Skip to main content
. 2006 Jul 24;353(2):474–481. doi: 10.1016/j.virol.2006.06.011

Fig. 3.

Fig. 3

Antiviral activity of IL-4 against SARS-CoV. Plaque titration of supernatant (A) or amount of SARS-CoV RNA (B) present in mock (control), 10 ng/ml IL-4 or IL-4/α-IL-4-treated cells that were infected with 105 TCID50 SARS-CoV. Susceptibility of IL-4-treated Vero E6 cells to SARS-CoV infection after removal of IL-4 conditioned medium and subsequent washing (C) and susceptibility of fresh Vero E6 cells to SARS-CoV after receiving IL-4 conditioned medium just before infection with 105 TCID50 SARS-CoV (D). Error bars indicate standard errors.